FOLH1 and prostate carcinoma: While advances in molecular imaging, particularly Prostate‐Specific Membrane Antigen‐Positron‐Emission/Computed Tomography (PSMA‐PET/CT), have significantly improved diagnostic accuracy compared to conventional imaging for prostate cancer (PCa), limited ability to detect micro metastases (<3 mm) remains a significant challenge for accurate staging.1, 2, 3, 4